Venetoclax

A simultaneous, multidrug, multi-targeted treatment regimen produced remissions in patients with certain types of relapsed or refractory diffuse large B-cell lymphoma in a phase 1b/phase 2 study.

The FDA placed a clinical hold on studies evaluating magrolimab for the treatment of acute myeloid leukemia and myelodysplastic syndromes, according to a statement released by the manufacturer.

SAN DIEGO — Akriti Jain, MD, highlights presentations from ASH Annual Meeting and Exposition focused on triplet combination therapy for patients with acute myeloid leukemia.

SAN DIEGO — Akriti Jain, MD, spoke with Healio about combination therapy with venetoclax for acute myeloid leukemia presented at ASH Annual Meeting and Exposition.

SAN DIEGO — In this video, Akriti Jain, MD, discusses a new targeted monotherapy being used for patients with acute myeloid leukemia, tuspetinib.

SAN DIEGO — In this video, Akriti Jain, MD, provides two updates on intensive treatment regimens for acute myeloid leukemia presented at ASH Annual Meeting and Exposition.

SAN DIEGO — In this video, Catherine Lai, MD, MPH, highlights early phase studies presented at ASH Annual Meeting and Exposition that investigated triplet therapy in acute myeloid leukemia.

SAN DIEGO — In this video, Catherine Lai, MD, MPH, spoke with Healio about patients with newly diagnosed or relapsed acute myeloid leukemia who stopped treatment with azacitidine/venetoclax after receiving one or more cycles past remission.

Healio spoke with Akriti Jain, MD, about the existing unmet needs in MDS patient care.

In this video, Eunice Wang, MD discusses acute myeloid leukemia highlights from the ASH Annual Meeting and Exposition.